Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis
Public ClinicalTrials.gov record NCT03401229. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients With Severe Nasal Polyposis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The aim of this present study is to investigate the use of benralizumab as treatment for severe nasal polyposis. The effect of benralizumab on nasal polyps will be assessed over a 56 weeks of treatment period in patients with severe bilateral nasal polyposis who are still symptomatic despite standard of care therapy, i.e current use of intranasal corticosteroids (INCS) and prior surgery and/or use of systemic corticosteroids. The first 200 patients that complete the 56-week treatment will have a 6 month follow-up (FU) period without dosing.
Study identification
- NCT ID
- NCT03401229
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 413 participants
Conditions and interventions
Conditions
Interventions
- Benralizumab 30 mg SC + Mometasone Furoate Biological
- Matching placebo SC + Mometasone Furoate Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 15, 2018 (Actual)
- Primary completion
- Jul 31, 2020 (Actual)
- Completion
- Jul 31, 2020 (Actual)
- Last update posted
- Oct 12, 2021
2018 – 2020
United States locations
- U.S. sites
- 48
- U.S. states
- 23
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35209 | — |
| Research Site | Fresno | California | 93720 | — |
| Research Site | Huntington Beach | California | 92647 | — |
| Research Site | La Mesa | California | 91942 | — |
| Research Site | Los Angeles | California | 90048 | — |
| Research Site | Los Angeles | California | 90095-1624 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Roseville | California | 95661 | — |
| Research Site | Walnut Creek | California | 94598 | — |
| Research Site | Centennial | Colorado | 80112 | — |
| Research Site | Glenwood Springs | Colorado | 81601 | — |
| Research Site | Washington D.C. | District of Columbia | 20037 | — |
| Research Site | Lake Mary | Florida | 32746 | — |
| Research Site | Atlanta | Georgia | 30308 | — |
| Research Site | Decatur | Georgia | 30030 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Site | Chicago | Illinois | 60657 | — |
| Research Site | Des Moines | Iowa | 50312 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | Louisville | Kentucky | 40220 | — |
| Research Site | Baltimore | Maryland | 21224 | — |
| Research Site | Boston | Massachusetts | 02111 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | Lincoln | Nebraska | 68510 | — |
| Research Site | Hewlett | New York | 11557 | — |
| Research Site | New Windsor | New York | 12553 | — |
| Research Site | New York | New York | 10001 | — |
| Research Site | New York | New York | 10011 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | New York | New York | 10022 | — |
| Research Site | New York | New York | 10075 | — |
| Research Site | New York | New York | 10128 | — |
| Research Site | Plainview | New York | 11803 | — |
| Research Site | The Bronx | New York | 10461 | — |
| Research Site | White Plains | New York | 10605 | — |
| Research Site | Charlotte | North Carolina | 28210 | — |
| Research Site | Winston-Salem | North Carolina | 27103 | — |
| Research Site | Oklahoma City | Oklahoma | 73120 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Research Site | Charleston | South Carolina | 29425 | — |
| Research Site | Conroe | Texas | 77304 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | North Logan | Utah | 84341 | — |
| Research Site | Norfolk | Virginia | 23507 | — |
| Research Site | Richmond | Virginia | 23235 | — |
| Research Site | Spokane | Washington | 99201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03401229, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 12, 2021 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03401229 live on ClinicalTrials.gov.